Mechanisms of neurodegeneration and progression

Mechanisms of neurodegeneration and progression: From mechanisms to therapies in Parkinson's disease

1 July 2016 - 
University of Copenhagen
Nørre Alle 20
Panum (Building 29). Room 29.01.30
School of Dentistry
 
Organisers: Maria Trinidad Herrero (University of Murcia, Spain); Micaela Morelli (University of Cagliari, Italy) Harry Steinbusch (University of Maastricht, The Netherlands) Neurotoxicity Society (NTS) Contact Persons: María Trinidad Herrero, Micaela Morelli and Harry Steinbusch E-mail: mtherrer@um.es; morelli@unica.it; h.steinbusch@maastrichtuniversity.nl

Programme

09.30: Welcome and introduction to the symposium. María Trinidad Herrero (President of NTS)

Micaela Morelli (Member of the NTS Council) Harry Steinbusch (President-Elect of NTS)

10.00: Neurobehavioural alterations after exposure to a glyphosate-based herbicide durig pregnancy and lactation.

Marta Antonelli. Buenos Aires, Argentina

10.30: Glucocorticoids modify the differentiation potential of human neuroepithelial-like cells via long-term alterations of the redox state.

Sandra Ceccatelli. Stockholm, Sweden

11.00: Discussion

11.15: In uence of administration setting and caffeine on the neuroin ammatory and neurotoxic effects of MDMA: relevance to dopaminergic neurodegeneration

Micaela Morelli. Cagliari, Italy

11.45: Electrical stimulation of the inferior colliculus: A promising animal model to study paradoxical kinesia

Liana Melo-Thomas. Marburg, Germany

12.45: Discussion

12.30: No and glutamate interaction in treatment of L-dopa-induced dyskinesia.

Elaine del Bel. Riberao Preto, Brazil

13.00: Striatal synaptic plasticity changes in l-dopa-induced dyskinesia. Rosario Moratalla. Madrid, Spain

13.30: Discussion
14.00: Lunch. Tables will be organised distributing sharing by speakers and

students.

15.30: Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease.

Gilles J. Guillemin. Sydney, Australia

4

MECHANISMS OF NEURODEGENERATION AND PROGRESSION: FROM MECHANISMS TO THERAPIES IN PARKINSON’S DISEASE

16.00: Matrix metalloproteinases in aging and in Parkinsonism: friends and foes to the dopaminergic neurons.

María Trinidad Herrero. Murcia, Spain

16.30: Discussion

16.45: Epigenetic changes and brainstem dysfunction in neuropsychiatric disorders - AD/PD/anx

Harry WM Steinbusch. Maastricht, The Netherlands

17.30: High potency TFEB inducers as novel therapeutics for Parkinson’s disease.

Julie K. Andersen. Novato, CA, USA

18.00: Discussion
18.15: Students presentation

Titles TBC

18.45: Concluding remarks.
María Trinidad Herrero, Micaela Morelli, Harry Steinbusch

20.00: Social Dinner. Venue TBC

 

TwitterLinkedInFacebook